

Breast Cancer Risk Reduction Medications For Zero Copay



Generic Name: NA

Therapeutic Class or Brand Name: Breast Cancer Risk Reduction Medications For Zero Copay

Applicable Drugs (if Therapeutic Class): Soltamox® (tamoxifen), raloxifene, tamoxifen

Preferred: Tamoxifen (generic), Raloxifene (generic)

Non-preferred: Soltamox® (tamoxifen)

Date of Origin: 12/2/2014

Date Last Reviewed / Revised: 9/8/2022

PRIOR AUTHORIZATION CRITERIA

(May be considered medically necessary when criteria I through IV are met)

- I. Member has an increased risk of breast cancer.
- II. Member meets ALL the following criteria A through C:
 - A. Is female.
 - B. Has no symptoms of breast cancer.
 - C. Does not have a prior diagnosis of ANY of the following 1 through 3:
 1. Breast cancer.
 2. Ductal carcinoma in situ (DCIS).
 3. Lobular carcinoma in situ (LCIS).
- III. Member meets ONE of the following criteria A, B, or C:
 - A. Request is for tamoxifen 20 mg per day.
 - B. Request is for raloxifene 60 mg per day AND criterion 1 is met:
 1. Member is post-menopausal.
 - C. Request is for non-preferred Soltamox® 20 mg per day and criterion 1 is met:
 1. Member has a documented inability to swallow tamoxifen tablets.
- IV. Minimum age requirement: 35 years old.

EXCLUSION CRITERIA

- Women who have a history of thromboembolic events (deep venous thrombosis, pulmonary embolus, stroke, or transient ischemic attack).

OTHER CRITERIA

- N/A

QUANTITY / DAYS SUPPLY RESTRICTIONS

Breast Cancer Risk Reduction Medications For Zero Copay



- Authorized in quantities of up to:
 - Tamoxifen, Soltamox®: 20 mg per day.
 - Raloxifene: 60 mg per day

APPROVAL LENGTH

- **Authorization:** 5 years.
- **Re-Authorization:** N/A.

APPENDIX

N/A

REFERENCES

1. U.S. Preventive Services. Final recommendation for breast cancer: Medication use to reduce risk. September 3, 2019. Accessed September 8, 2022. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction>.
2. Centers for Medicare & Medicaid Services. Affordable care act implementation FAQs - Set 18. Updated April 13, 2020. Accessed September 8, 2022. http://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/aca_implementation_faqs18.html.
3. Tamoxifen Citrate. Prescribing information. McKesson Corporation; 2020. Accessed September 8, 2022. <https://soltamox.com/wp-content/uploads/2019/12/soltamox-pi.pdf>.
4. Evista. Prescribing information. Eli Lilly and Co.; 2022. Accessed September 8, 2022. <https://pi.lilly.com/us/evista-pi.pdf>.

DISCLAIMER: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgement in providing the most appropriate care for their patients.